Updated:
Arthritis UK
Arthritis UK launched in 2018 as Versus Arthritis, the product of a merger between Arthritis Research UK and Arthritis Care—two legacy organizations with...
Arthritis UK
Arthritis UK launched in 2018 as Versus Arthritis, the product of a merger between Arthritis Research UK and Arthritis Care—two legacy organizations with decades of history in British medical philanthropy. The charity adopted its current name in 2025, streamlining its public identity. Headquartered at Copeman House in Chesterfield, the organization is governed by a Board of Trustees chaired by Kate Tompkins, with Chief Executive Deborah Alsina MBE running day-to-day operations since her appointment in March 2022. The charity is a core member of both the Association of Medical Research Charities and the Richmond Group of Charities, a coalition of leading UK health and social care organizations. The portfolio splits between an endowed investment pool and direct programmatic grant-making. On the research side, Arthritis UK funds academic and clinical projects across the UK, targeting rheumatoid arthritis, osteoarthritis, and musculoskeletal pain mechanisms. A signature partnership is the Advanced Pain Discovery Platform, co-developed with UK Research and Innovation (UKRI), which backs translational science aimed at chronic pain treatment. The charity also co-funds with the Kennedy Trust for Rheumatology Research, a major Oxford-based biomedical funder. These collaborations place Arthritis UK in the center of UK rheumatology research infrastructure rather than at a passive grant-making remove. Its investment property holdings and the Maisie Lewis Fund augment its grant-making capacity. Team scale and precise assets-under-management are not publicly disclosed as standard practice for UK charitable foundations, though annual research expenditure runs in the tens of millions of pounds. The organization maintains commercial investment property in the UK alongside its research endowment. Deborah Alsina's appointment in March 2022 brought a seasoned charity-sector executive to the helm, succeeding a period of post-merger integration. HM Queen Camilla serves as Patron, providing institutional visibility that supports fundraising and advocacy efforts. The charity's governance structure separates its investment committee from its research strategy board, a common architecture for UK medical foundations. In 2025 the organization rebranded from Versus Arthritis to Arthritis UK, a move to sharpen public recognition after seven years operating under the post-merger name. Arthritis UK's structural differentiator is its dual role as a convener of UK-wide research consortia and a direct patient-support operation. Unlike foundations that simply write cheques to university labs, it co-designs research platforms with government funders like UKRI and co-invests alongside specialist rheumatology trusts, creating leverage on its endowment that a pure capital allocator cannot achieve. This operational posture makes it a node in UK musculoskeletal science rather than a passive funder, a distinction that shapes both its talent attraction to the board and its influence on national research priorities.
General information
Firm type
Endowment / Foundation
Year founded
2018
Location
Region
Europe
Country
United Kingdom
City
Chesterfield
Corporate office
Copeman House, St Mary's Gate, Chesterfield, S41 7TD, United Kingdom
Principals
Deborah Alsina MBE
Chief Executive Officer
Kate Tompkins
Chair of the Board of Trustees
Sector focus
Frequently asked questions
Who runs investment decisions at Arthritis UK?
Arthritis UK's endowment is managed under the oversight of its Board of Trustees, chaired by Kate Tompkins, with a dedicated investment committee handling portfolio decisions. The charity has not publicly named its investment committee members or external managers, though UK foundations of this scale typically employ a mix of in-house oversight and outsourced management. CEO Deborah Alsina MBE, appointed in March 2022, holds executive responsibility for the organization's overall financial strategy.
How does Arthritis UK source its research partnerships?
Arthritis UK co-designs research platforms with government funders and peer foundations rather than relying solely on open calls for proposals. Its Advanced Pain Discovery Platform, developed jointly with UK Research and Innovation (UKRI), is a flagship example of this proactive approach. The charity also maintains a long-standing co-funding relationship with the Kennedy Trust for Rheumatology Research, creating a network of pre-vetted academic and clinical partners.
What is Arthritis UK's relationship to the Kennedy Trust for Rheumatology Research?
Arthritis UK and the Kennedy Trust are frequent co-funders of rheumatology research initiatives and platforms in the UK. The Kennedy Trust is a significant biomedical funder based at the University of Oxford, and the two organizations collaborate on translational science projects rather than competing for grant applications. This partnership effectively pools their respective endowments to back larger-scale studies than either could fund independently.
Where does Arthritis UK's funding come from?
The charity's income derives from a mix of public donations, legacy gifts, and returns on its endowed investment portfolio. Its property holdings, including Copeman House in Chesterfield and additional commercial investment property in the UK, generate rental income that supports operations. The Maisie Lewis Fund, a named sub-fund within the charity, provides additional grant-making capacity.
What is Arthritis UK's research focus?
The charity funds research across the full spectrum of arthritis and musculoskeletal conditions, including rheumatoid arthritis, osteoarthritis, and chronic pain mechanisms. Its strategy emphasizes translational science that moves laboratory findings into clinical practice, with a particular concentration on pain management. Through its partnerships with UKRI and the Kennedy Trust, it has directed substantial funding toward the Advanced Pain Discovery Platform and related consortia.
Is Arthritis UK a grant-making foundation or a research institute?
Arthritis UK is a grant-making foundation that funds external researchers at UK universities and hospitals, not a research institute with its own laboratories. However, its approach is more hands-on than a passive grant-maker: it co-designs research platforms with partners like UKRI, co-funds alongside specialist trusts, and advocates for national research priorities. This bridges the gap between pure philanthropy and an operating research organization.
Does Arthritis UK manage direct investments or only traditional endowment assets?
Arthritis UK holds a mix of traditional endowment assets and direct property investments, including its Chesterfield headquarters and additional commercial investment property in the UK. The charity has not publicly disclosed its full portfolio composition or whether it engages in alternative investments. UK charitable foundations of comparable scale typically hold diversified portfolios including equities, fixed income, and property.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on endowments & foundations?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: